| Cancer therapeutics and mechanisms | Lifetime | 30 | SE 1 | 99.70 |
| Drug Transport and Resistance Mechanisms | Lifetime | 46 | SE 3 | 99.66 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 62 | SE 1 | 99.40 |
| Neuroendocrine Tumor Research Advances | Lifetime | 82 | SE 3 | 99.55 |
| HER2/EGFR in Cancer Research | Lifetime | 87 | SE 2 | 99.57 |
| Economic and Financial Impacts of Cancer | Lifetime | 54 | SE 2 | 99.05 |
| Lung Cancer Research Studies | Lifetime | 139 | SE 2 | 99.36 |
| Neuroblastoma Research and Treatments | Lifetime | 105 | SE 3 | 99.13 |
| Neutropenia and Cancer Infections | Lifetime | 60 | SE 2 | 99.25 |
| Cancer Treatment and Pharmacology | Lifetime | 193 | SE 3 | 99.40 |
| Medical Imaging Techniques and Applications | Lifetime | 304 | SE 6 | 98.86 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 423 | SE 9 | 99.22 |
| Cancer Research and Treatments | Lifetime | 175 | SE 4 | 98.74 |
| Cell death mechanisms and regulation | Lifetime | 114 | SE 4 | 98.96 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 24 | SE 1 | 98.23 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 445 | SE 2 | 98.99 |
| Ovarian cancer diagnosis and treatment | Lifetime | 271 | SE 2 | 98.74 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 69 | SE 1 | 98.26 |
| Colorectal Cancer Treatments and Studies | Lifetime | 451 | SE 4 | 98.64 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 380 | SE 8 | 98.07 |
| Peptidase Inhibition and Analysis | Lifetime | 638 | SE 7 | 97.87 |
| Cancer Genomics and Diagnostics | Lifetime | 884 | SE 14 | 98.44 |
| Lung Cancer Treatments and Mutations | Lifetime | 832 | SE 1 | 98.33 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 891 | SE 10 | 98.14 |
| Cancer-related Molecular Pathways | Lifetime | 583 | SE 11 | 98.01 |
| Chemotherapy-related skin toxicity | Lifetime | 79 | SE 1 | 96.66 |
| Breast Cancer Treatment Studies | Lifetime | 780 | SE 21 | 97.80 |
| Testicular diseases and treatments | Lifetime | 272 | SE 6 | 97.05 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 239 | SE 6 | 95.06 |
| Hematological disorders and diagnostics | Lifetime | 422 | SE 7 | 94.43 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 496 | SE 10 | 94.53 |
| NF-κB Signaling Pathways | Lifetime | 742 | SE 4 | 94.02 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 29 | SE 1 | 98.40 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 376 | SE 5 | 96.46 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 797 | SE 1 | 96.94 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 331 | SE 11 | 94.56 |
| Medical Imaging Techniques and Applications | 2021-2025 | 434 | SE 3 | 94.87 |
| Immunotherapy and Immune Responses | 2021-2025 | 793 | SE 6 | 91.99 |
| HER2/EGFR in Cancer Research | 2021-2025 | 381 | SE 7 | 93.65 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 634 | SE 11 | 89.29 |
| Pharmaceutical Economics and Policy | 2021-2025 | 598 | SE 4 | 77.81 |
